ReportWire

Tag: information

  • The Lab Leak Will Haunt Us Forever

    The Lab Leak Will Haunt Us Forever

    [ad_1]

    The lab-leak theory lives! Or better put: It never dies. In response to new but unspecified intelligence, the U.S. Department of Energy has changed its assessment of COVID-19’s origins: The agency, which had previously been undecided on the matter, now rates a laboratory mishap ahead of a natural spillover event as the suspected starting point. That conclusion, first reported over the weekend by The Wall Street Journal, matches up with findings from the FBI, and also a Senate Minority report out last fall that called the pandemic, “more likely than not, the result of a research-related incident.”

    Then again, the new assessment does not match up with findings from elsewhere in the federal government. In mid-2021, when President Biden asked the U.S. intelligence community for a 90-day review of the pandemic’s origins, the response came back divided: Four agencies, plus the National Intelligence Council, guessed that COVID started (as nearly all pandemics do) with a natural exposure to an infected animal; three agencies couldn’t decide on an answer; and one blamed a laboratory accident. DOE’s revision, revealed this week, means that a single undecided vote has flipped into the lab-leak camp. If you’re keeping count—and, really, what else can one do?—the matter still appears to be decided in favor of a zoonotic origin, by an updated score of 5 to 2. The lab-leak theory remains the outlier position.

    Are we done? No, we aren’t done. None of these assessments carries much conviction: Only one, from the FBI, was made with “moderate” confidence; the rest are rated “low,” as in, hmm we’re not so sure. This lack of confidence—as compared with the overbearing certainty of the scientists and journalists who rejected the possibility of a lab leak in 2020—will now be fodder for what could be months of Congressional hearings, as House Republicans pursue evidence of a possible “cover-up.” But for all the Sturm und Drang that’s sure to come, the fundamental state of knowledge on COVID’s origins remains more or less unchanged from where it was a year ago. The story of a market origin matches up with recent history and an array of well-established facts. But the lab-leak theory also fits in certain ways, and—at least for now—it cannot be ruled out. Putting all of this another way: ¯_(ツ)_/¯.

    That’s not to say that it’s a toss-up. All of the agencies agree, for instance, that SARS-CoV-2 was not devised on purpose, as a weapon. And several bits of evidence have come to light since Biden ordered his review—most notably, a careful plot of early cases from Wuhan, China, that stamps the city’s Huanan market complex as the outbreak’s epicenter. Many scientists with relevant knowledge believe that COVID started in that market—but their certainty can waver. In that sense, the consensus on COVID’s origins feels somewhat different from the one on humans’ role in global warming, though the two have been pointedly compared. Climate experts almost all agree, and they also feel quite sure of their position.

    The central ambiguity, such as it is, of COVID’s origin remains intact and perched atop a pair of improbable-seeming coincidences: One concerns the Huanan market, and the other has to do with the Wuhan Institute of Virology, where Chinese researchers have specialized in the study of bat coronaviruses. If COVID really started in the lab, one position holds, then it would have to be a pretty amazing coincidence that so many of the earliest infections happened to emerge in and around a venue for the sale of live, wild animals … which happens to be the exact sort of place where the first SARS-coronavirus pandemic may have started 20 years ago. But also: If COVID really started in a live-animal market, then it would have to be a similarly amazing coincidence that the market in question happened to be across the river from the laboratory of the world’s leading bat-coronavirus researcher … who happened to be running experiments that could, in theory, make coronaviruses more dangerous.

    One might argue over which of these coincidences is really more surprising; indeed, that’s been the major substance of this debate since 2020, and the source of endless rancor. In theory, further studies and investigations would help resolve some of this uncertainty—but these may never end up happening. A formal inquiry into the pandemic’s origin, set up by the World Health Organization, had intended to revisit its claim from early 2021 that a laboratory source was “extremely unlikely.” Now that project has been shelved in the face of Chinese opposition, and the Wuhan Institute of Virology has long since stopped responding to requests for information from its U.S.-based research partners and the NIH, according to an inspector general’s report from the Department of Health and Human Services.

    In the meantime, the smattering of facts that have been introduced into the lab-leak debates over the past two years, have been, at times, maddeningly opaque—like the unnamed, “new intelligence” that swayed the Department of Energy. (For the record, The New York Times reports that each of the agencies investigating the pandemic’s origin had access to this same intelligence; only DOE changed its assessment to favor the lab-leak explanation as a result.) We’re only told that certain fresh and classified information has changed the minds of some (but only some) unnamed analysts who now believe (with limited assurance) that a laboratory origin is most likely. Well, great, I guess that settles it.

    When more specific information does crop up, it tends to vary in the telling over time; or else it’s promptly pulverized by its partisan opponents. The Journal’s reporting, for instance, mentions a finding by U.S. intelligence that three researchers at the Wuhan Institute of Virology became ill in November 2019, in what could have been the initial cluster of infection. But how much is really known about those sickened scientists? The specifics vary with the source. In one telling, a researcher’s wife was sickened, too, and died from the infection. Another adds the seemingly important fact that the researchers were “connected with gain-of-function research on coronaviruses.” But the unnamed current and former U.S. officials who pass along this sort of information can’t even seem to settle on its credibility.

    Or consider the reporting, published last October by ProPublica and Vanity Fair, on a flurry of Chinese Community Party communications from the fall of 2019. These were interpreted by Senate researcher Toy Reid to mean that the Wuhan Institute of Virology had undergone a major biosafety crisis that November—just when the COVID outbreak would have been emerging. Critics ridiculed the story, calling it a “train wreck” premised on a bad translation. In response ProPublica asked three more translators to verify Reid’s reading, and claimed they “all agreed that his version was a plausible way to represent the passage,” and that the wording was ambiguous.

    Maybe this is just what happens when you’re trapped inside an information vacuum: Any scrap of data that happens to float by will push you off in new directions.

    [ad_2]

    Daniel Engber

    Source link

  • SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder – Medical Marijuana Program Connection

    SciSparc Signs Agreement for the Supply of CBD-rich Cannabis Oil for its Clinical Trial on Children with Autism Spectrum Disorder – Medical Marijuana Program Connection

    [ad_1]

    The cannabis oil will be used as a part of the Companys proprietary SCI-210 treatment combination of CBD and CannAmide™

     TEL AVIV, Israel, Feb. 27, 2023 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of  the central nervous system, today announced it has signed an agreement with Israel’s leading and pioneer manufacturer and distributer of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., Israel (TASE: TKUN), to supply CBD-rich oil from Cannbit strains by, to be used as part of its proprietary SCI-210 treatment, which is a combination of CBD and CannAmide™. SCI-210 treatment will be used in the Company’s clinical trial (“Trial”) on children with autism spectrum disorder (“ASD”).

    The Trial will be conducted at the Soroka University Medical Center, led by Prof. Gal Meiri, head of the Soroka Preschool Psychiatry Unit. The Company has already secured approvals from the Israeli Ministry of Health as well as the Ethics Committee of the Soroka University Medical Center to conduct the Company’s clinical trial.

    The Trial will evaluate the safety, tolerability and efficacy of SciSparc’s drug candidate SCI-210, a proprietary combination of cannabidiol (“CBD”) and CannAmide™, in comparison to CBD monotherapy in children with ASD. The study design is a 20-week, randomized double-blind…

    [ad_2]

    MMP News Author

    Source link

  • Do You Really Want to Read What Your Doctor Writes About You?

    Do You Really Want to Read What Your Doctor Writes About You?

    [ad_1]

    You may not be aware of this, but you can read everything that your doctor writes about you. Go to your patient portal online, click around until you land on notes from your past visits, and read away. This is a recent development, and a big one. Previously, you always had the right to request your medical record from your care providers—an often expensive and sometimes fruitless process—but in April 2021, a new federal rule went into effect, mandating that patients have the legal right to freely and electronically access most kinds of notes written about them by their doctors.

    If you’ve never heard of “open notes,” as this new law is informally called, you’re not the only one. Doctors say that the majority of their patients have no clue. (This certainly has been the case for all of the friends and family I’ve asked.) If you do know about the law, you likely know a lot about it. That’s typically because you’re a doctor—one who now has to navigate a new era of transparency in medicine—or you’re someone who knows a doctor, or you’re a patient who has become intricately familiar with this country’s health system for one reason or another.

    When open notes went into effect, the change was lauded by advocates as part of a greater push toward patient autonomy and away from medical gatekeeping. Previously, hospitals could charge up to hundreds of dollars to release records, if they released them at all. Many doctors, meanwhile, have been far from thrilled about open notes. They’ve argued that this rule will introduce more challenges than benefits for both patients and themselves. At worst, some have fretted, the law will damage people’s trust of doctors and make everyone’s lives worse.

    A year and a half in, however, open notes don’t seem to have done too much of anything. So far, they have neither revolutionized patient care nor sunk America’s medical establishment. Instead, doctors say, open notes have barely shifted the clinical experience at all. Few individual practitioners have been advertising the change, and few patients are seeking it out on their own. We’ve been left with a partially implemented system and a big unresolved question: How much, really, should you want to read what your doctor is writing about you?


    The debate about open notes can be boiled down to a matter of practicality versus idealism. You’d be hard-pressed to find anyone, doctor or otherwise, who argues against transparency for patients in principle. At the same time, few people I spoke with for this article believe that the new rule has been put in place all that smoothly. For care providers, the primary concern has been the trouble that can come with writing notes for a new audience. Notes, generally scribbled in shorthand incomprehensible to the unknowing eye, have traditionally served doctors, and doctors alone. They allowed physicians to stay up to date on their patients and share information with colleagues for input on cases.

    Some doctors told me they worry that open notes could result in distress for patients who read something they don’t understand, and that highly technical language could make something sound worse than it is. Oncology, for instance, can involve an onslaught of potentially concerning terminology. (Psychotherapy notes are exempt from the new rule.) Other doctors fear that valuable information can be lost if they go too far in de-jargonizing notes to make them patient-friendly. Or that de-jargonizing notes is simply unfeasible. “Let’s say you came to me with pain and pointed to your mid-clavicular line. I’d just put ‘MCL,’” says Aldo Peixoto, a nephrologist at Yale. “But if I were writing for you to understand, I’d have to say ‘pain on the top-right portion of her abdomen in the line that runs from the middle of her clavicle,’ and so on. Rather than writing four lines of prose, I could’ve used literally three letters.”

    If that sounds quibbling, consider the trade-offs. Less time for doctors can translate into less time for patients. Many clinicians already write notes well into the evening. Certainly, the pandemic hasn’t helped. Some doctors told me that if they find themselves in a dilemma of either writing notes in less-efficient, plain language or fielding worried patient calls and messages, exhausted practitioners will face yet another burden. And then there’s the matter of trust. Jack Resneck, the president of the American Medical Association, the nation’s largest professional group of doctors and medical students, told me that doctors can need time and space with patients to get them to open up and be receptive to guidance through difficult situations. If these patients were to see notes too soon, Resneck said, they might “immediately flee and not come back to see you.”

    As doctors have spent more time dealing with open notes, many have eased off their strongest objections. Some, including Resneck and the AMA, have warmed up to the new rule as certain exceptions have been granted, such as allowing doctors whose patients have parents or partners with access to their notes to omit certain details from their write-ups for privacy reasons. Other physicians seem to be coming to a somewhat awkward realization: On a practical level, many concerns about how this change affects patients are irrelevant, because most patients don’t yet know they have instant access to their notes in the first place. Every doctor I spoke with for this story told me that their patients were largely unaware. Many doctors and hospitals are not going out of their way to inform people about the new rule, so unless patients are particularly on top of shifting rules within our convoluted health-care system, they’re unlikely to encounter the notes on their own. Kerin Adelson, an oncologist at Yale, admitted she didn’t know how to find notes in her own patient portal. She spent several minutes with me on the phone fumbling through different tabs to locate them.

    Fans of open notes are frustrated that there is not a greater push for awareness. Even acknowledging that the new system has its shortcomings, many argue that the only way to make things better is to get people invested in the access they’ve recently been granted. Lydia Dugdale, a primary-care doctor at Columbia University, worries about ensuring equity. “Things like socioeconomic status, education, literacy: All of those issues affect the degree to which any given patient is going to want to read and correct and interrogate his or her health record,” she told me. Tom Delbanco, a Harvard doctor and one of the co-founders of OpenNotes, an initiative that spearheaded the push for access to doctors’ notes in the U.S., believes that the effort required to refrain from using “bad words” in notes is minor, and that it shouldn’t make any significant demands on clinicians’ schedules. Doctors who are now taking more time to write notes because of the change, he told me, “probably ought to because they’ve been writing lousy notes.”

    Open notes can be valuable for people with chronic conditions and their caregivers, who need to stay in the know. Liz Salmi, the communications and patient-initiatives director at OpenNotes, told me about pulling her full medical record eight years into dealing with brain cancer, before notes were easily and freely available. The document was 4,839 pages. To get a PDF, she said, she had to pay $15 for each DVD it was uploaded to, and her records spanned multiple discs. But the information was worth it: Having access to the record gave Salmi a way to remember all of the crucial bits of information she’d gotten piecemeal from various doctors.


    The fact that many people have no idea open notes exist doesn’t change the deeply personal questions at stake in the debate about whether the notes do more good or harm—questions that everyone must confront in one way or another in dealing with America’s medical system, whether or not they fully realize it. How much information do you truly want about your health, and how much do you trust your doctor to deliver it to you? What is a doctor’s role in informing people about their health?

    Open notes are only part of this conversation. The new law also requires that test results be made immediately available to patients, meaning that patients might see their health information before their physician does. Although this is fine for the majority of tests, problems arise when results are harbingers of more complex, or just bad, news. Doctors I spoke with shared that some of their patients have suffered trauma from learning about their melanoma or pancreatic cancer or their child’s leukemia from an electronic message in the middle of the night, with no doctor to call and talk through the seriousness of that result with. This was the case for Tara Daniels, a digital-marketing consultant who lives near Boston. She’s had leukemia three times, and learned about the third via a late-night notification from her patient portal. Daniels appreciates the convenience of open notes, which help her keep track of her interactions with various doctors. But, she told me, when it comes to instant results, “I still hold a lot of resentment over the fact that I found out from test results, that I had to figure it out myself, before my doctor was able to tell me.”

    As Americans continue to age, get sick, and navigate the health-care system, many of us may become more invested in the idea of open notes. Until they play a more widespread role in people’s lives, however, the most pressing question about whether you truly want instant access to all your medical information might be how it affects your doctor’s life. Many physicians have come around to open notes, or at least have realized that allowing patients to see what has been written about them is not always a huge bother. But the bigger question of just how quickly patients should be able to access medical information, and how soon doctors should be available to help patients process it, continues to plague physicians. The advent of immediate data sharing “has been a major problem in terms of physician quality of life, and that’s eroded across the board,” Peixoto told me. “Doctors don’t want to be connected all the time. They actually have their lives.”

    Where we have landed, then, is an in-between. Patients can read their doctor’s notes and view test results at any hour of the day, but we can access our providers only at certain times. There is likely room for refinement. Allowing a patient to select whether they receive test results from their physician or their portal, or see notes only after their doctor has had the opportunity to walk them through the terminology used, for instance, could make all the difference, some doctors told me. For now, it’s worth asking yourself whether you want to access your patient portal alone, or want to wait until you can get your doctor on the line.

    [ad_2]

    Zoya Qureshi

    Source link